Outset Medical's First Refresh Win with HCA Marks a Strategic Inflection
The Refresh Cycle Begins
Outset Medical's Q2 2026 call was anchored by a landmark deal: “We are privileged to have signed a $40 million refresh agreement with HCA Healthcare.” — Leslie Trigg, Chair and Chief Executive Officer · 2026-08-06 This is the company's first refresh win, and it signals a new phase of growth beyond new installs. The refresh cycle, which Leslie framed as a multi-year opportunity for roughly 3,000 consoles and up to $150 million in revenue, is now crystallizing into actual orders.
The refresh opportunity was entirely absent from prior quarters' narrative, which centered on capital sales lumpiness and pipeline building. In the May 2026 call, Leslie spoke about an 'emerging refresh opportunity' “with existing customers who have older Tableau fleets and have conveyed an intent to buy replacement units in future quarters and in future years.” — Leslie L. Trigg, Chair and Chief Executive Officer · 2026-05-07 Now it's a signed contract, and the refresh agreement with HCA facilities provides a contracted backlog that adds visibility to 2028.
From a strategic standpoint, this is a direct validation of the installed base's value. HCA, after evaluating comparative outcomes, chose to recommit to Tablo. The clinical excellence team, a new structured customer success program, likely played a role, as Leslie noted: “A strong customer experience was instrumental in securing a meaningful recent commercial win.” — Leslie Trigg, Chair and Chief Executive Officer · 2026-08-06
Commercial Execution and the Customer Success Engine
The company is scaling its commercial organization under new EVP Derek Elliott. The quarter saw the highest number of successful new site implementations in several years, with a Texas system training over 100 nurses and delivering 956 treatments in 60 days. The clinical excellence team is now paired with each customer to optimize value, and an independent voice-of-customer assessment yielded a net promoter-like score of 8.8/10.
This focus on customer expansion is a deliberate shift from the earlier emphasis on new customer acquisition. Leslie emphasized: "We're increasingly seeing customers expand their use of Tablo, both by deploying the technology at additional sites across their health systems and by broadening use within existing facilities." The refresh deal with HCA is the most tangible evidence of this expansion strategy working.
Prior calls in 2025 had a different tone. On the May 2025 call, the focus was on sales transformation and new sales force tenure. Leslie described the commercial organization as “dramatically different” — Leslie L. Trigg, Chair and Chief Executive Officer · 2025-08-06 but the conversation was still about closing new enterprise deals. Now the narrative has pivoted to monetizing the installed base through refresh and same-store expansion, a more predictable and potentially higher-margin revenue stream.
Financial Discipline and the Road to Profitability
Financially, the quarter was solid. Revenue of $31.6M was up 1% YoY and 14% sequentially, with non-GAAP gross margin expanding to 42.2% from 38.4% a year earlier. Operating expenses were flat YoY, and the operating loss improved 7% to $12.4M. Cash use of $9.5M in Q2 keeps the company on track to use less than $40M for the year, leaving about $151M in cash at quarter end.
Management reiterated full-year revenue guidance of $125–130M, pointing to a strong pipeline and the HCA backlog. Renee Gaeta noted: “our confidence in this outlook is supported by a strong commercial pipeline and the foundational contracted backlog provided by the HCA refresh agreement.” — Renee Gaeta, Chief Financial Officer · 2026-08-06
This marks our first refresh win, and that's an important milestone as we continue to capitalize on a refresh cycle that, over the next several years, may include roughly 3,000 consoles and up to $150 million in console revenue opportunity.
The financial trajectory shows improving operating leverage, but the big question remains the durability of the refresh cycle. If HCA is the first of many, the company could accelerate growth beyond the low-single-digit revenue gains it has posted recently. Conversely, consumable revenue continues to face difficult comparables, though Leslie stressed that utilization is stable.
In summary, Outset Medical is no longer just a story about new customer wins; it's now a story about extracting value from its installed base through refresh and expansion. The HCA deal is a proof point that could catalyze similar agreements with other large health systems, making this a potential inflection point for the business.